FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.

GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis

February 26, 2026

Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer

February 26, 2026

Source link

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis

Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer

Top 5 African cities with the smoothest traffic mid-2025

Meta buys stake in Scale AI, raising antitrust concerns

Meta buys stake in Scale AI, raising antitrust concerns

Leave a Reply Cancel reply

RECOMMENDED NEWS

Elon Musk Mocked Ukraine, and Russian Trolls Went Wild

Solve Intelligence helps attorneys draft patents for IP analysis and generation

Merck to complete acquisition of Cidara Therapeutics

Inside ‘Culture Shock’ at Goldman Sachs, ‘Black Capitalism’

POPULAR NEWS

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

Mahama attends Liberia’s 178th independence anniversary

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

Related posts

Top 5 African cities with the smoothest traffic mid-2025

Meta buys stake in Scale AI, raising antitrust concerns

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS